Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Multiple Myeloma
100%
Myeloma
63%
Dexamethasone
50%
Polyethylene Terephthalate
50%
Pomalidomide
50%
Lenalidomide
50%
Fluorodeoxyglucose F 18
50%
Neurotoxicity
16%
Tolerability
16%
Bone Disease
13%
Bone Lesion
9%
Progression Free Survival
8%
Adverse Event
8%
Motor Neuropathy
8%
Neuropathy
8%
Sensory Neuropathy
8%
Medicine and Dentistry
Whole Body MRI
50%
Fluorodeoxyglucose F 18
50%
Multiple Myeloma
50%
Diagnostic Performance
50%
Positron Emission Tomography-Computed Tomography
50%
Skeletal Survey
18%
Bone Lesion
9%
Bone Disease
9%
Myeloma
9%
Immunology and Microbiology
Pomalidomide
50%
Lenalidomide
50%
Multiple Myeloma
50%
Dexamethasone
50%
Progression Free Survival
9%
Virus Reactivation
7%
